Galectin Therapeutics
GALT
75 hedge funds and large institutions have $22.7M invested in Galectin Therapeutics in 2021 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 25 reducing their positions, and 10 closing their positions.
1.46% less ownership
Funds ownership: 18.87% → 17.41% (-1.5%)
4% less funds holding
Funds holding: 78 → 75 (-3)
5% less capital invested
Capital invested by funds: $23.9M → $22.7M (-$1.25M)
15% less call options, than puts
Call options by funds: $226K | Put options by funds: $266K
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
40% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$653K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$282K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$116K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$82.5K |
| 5 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
+$58.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
-$1.57M |
| 2 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$402K |
| 3 |
Russell Investments Group
London,
United Kingdom
|
-$237K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$171K |
| 5 |
OSAM
O'Shaughnessy Asset Management
Stamford,
Connecticut
|
-$162K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
76
Russell Investments Group
London,
United Kingdom
| – | -$237K | -106,075 | Closed |
|
|
OSAM
77
O'Shaughnessy Asset Management
Stamford,
Connecticut
| – | -$162K | -72,515 | Closed |
|
78
Two Sigma Investments
New York
| – | -$135K | -60,181 | Closed |
|
79
Citadel Advisors
Miami,
Florida
| – | -$43.3K | -19,333 | Closed |
|
|
RJFSA
80
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| – | -$41K | -18,229 | Closed |
|
|
FI
81
FormulaFolio Investments
Grand Rapids,
Michigan
| – | -$28K | -12,710 | Closed |
|
|
AIC
82
Ameritas Investment Company
Lincoln,
Nebraska
| – | -$24K | -10,782 | Closed |
|
|
CS
83
Credit Suisse
Zurich,
Switzerland
| – | -$23K | -10,210 | Closed |
|
|
TPWA
84
TRUE Private Wealth Advisors
Salem,
Oregon
| – | -$2K | -1,000 | Closed |
|
GALT Hedge Fund Activity: Q1 2021 in Review
75 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2021, worth a combined $22.7M — down 5.2% from $23.9M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of GALT and 7 opened new positions — a net loss of 3 holders — while 25 trimmed existing stakes and 15 added.
The largest buyer was Renaissance Technologies, adding an estimated $653K. The largest seller was D.A. Davidson & Co, cutting an estimated $1.57M.
- 75 institutional investors held Galectin Therapeutics (GALT) as of Q1 2021, down from 78 in Q4 2020.
- Funds reported $22.7M of Galectin Therapeutics stock for Q1 2021, down 5.2% quarter-over-quarter.
- 7 funds opened new Galectin Therapeutics positions in Q1 2021 and 10 closed out, a net change of -3 holders.
- The largest Galectin Therapeutics buyer in Q1 2021 was Renaissance Technologies, an estimated $653K added.
- The largest Galectin Therapeutics seller in Q1 2021 was D.A. Davidson & Co, an estimated $1.57M sold.
Based on aggregated 13F filings for Q1 2021.